摘要
心力衰竭(心衰)的多种病理生理改变均涉及相关生物标志物的表达,生物标志物在心衰预测、诊断、指导治疗及预后评估方面发挥着重要的作用。监测心衰患者生物标志物水平是心衰管理的重要部分。本共识结合国内外最新研究结果和我国实践经验,对目前心衰生物标志物临床应用进行总结,旨在指导和规范我国心衰患者的生物标志物管理,从而改善心衰患者的诊疗和预后。
The pathophysiologic mechanisms of heart failure involve the expression of associated biomarkers,which may play an important role in the prediction,diagnosis,treatment guidance and prognosis for heart failure.Monitoring the levels of biomarkers is of importance in the management of patients with heart failure.This expert consensus summarizes the clinical application of biomarkers for heart failure according to the updated research results home and abroad and the practical experience of our country,with the aim to guide and standardize the management of biomarkers,so as to improve the diagnosis,treatment and prognosis of patients with heart failure in China.
出处
《中华心力衰竭和心肌病杂志（中英文）》
2022年第3期175-192,共18页
Chinese Journal of Heart Failure and Cardiomyopathy
